|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12345678910111213...6566» |
- | Trial completion, Enrollment change: UK_DR-TB: Improving the Management of Drug Resistant Tuberculosis in the UK (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=630, Completed, Sponsor: University College, London
Recruiting --> Completed | N=1282 --> 630
- | New trial: CONRADBV: Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=35, Completed, Sponsor: CONRAD
- ||||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
New P4 trial: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea (clinicaltrials.gov) - Dec 19, 2017
P4, N=3960, Recruiting, Sponsor: GlaxoSmithKline
- | New P1 trial: HOPS: Phase 1 Safety and Immunogenicity of Meningococcal Vaccine (clinicaltrials.gov) - Dec 19, 2017
P1, N=36, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
- | Trial completion: HOPS: Phase 1 Safety and Immunogenicity of Meningococcal Vaccine (clinicaltrials.gov) - Dec 19, 2017
P1, N=36, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Completed | N=1282 --> 630 Active, not recruiting --> Completed
- |||| vancomycin / Generic mfg.
Trial primary completion date: Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis (clinicaltrials.gov) - Dec 19, 2017
P3, N=150, Recruiting, Sponsor: Kurobe LLC
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Apr 2018
- | Trial completion: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT (clinicaltrials.gov) - Dec 18, 2017
P=N/A, N=115, Completed, Sponsor: Sunnybrook Health Sciences Centre
Trial primary completion date: Dec 2017 --> Apr 2018 Recruiting --> Completed
- | Trial completion: Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Dec 18, 2017
P2, N=109, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Completed
- | Trial primary completion date: Simplified GBS Screening and Prevalence of ESBL in Pregnant Women (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=480, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Completed Trial primary completion date: Dec 2017 --> Mar 2018
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Trial primary completion date: Systems Biology of PNEUMOVAX®23 and PREVNAR 13® (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=88, Completed, Sponsor: Emory University
Trial primary completion date: Dec 2017 --> Mar 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017
- | Trial completion, Enrollment change, Head-to-Head: FIND: Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests (clinicaltrials.gov) - Dec 12, 2017
P=N/A, N=504, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017 Enrolling by invitation --> Completed | N=900 --> 504
- |||| Trial primary completion date: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen (clinicaltrials.gov) - Dec 12, 2017
P3, N=1080, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Enrolling by invitation --> Completed | N=900 --> 504 Trial primary completion date: Nov 2017 --> Mar 2018
- |||| Trial primary completion date: Phase III Clinical Study of Efficacy and Safety of Vaccae (clinicaltrials.gov) - Dec 12, 2017
P3, N=10000, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Trial primary completion date: Nov 2017 --> Mar 2018 Trial primary completion date: Nov 2017 --> Apr 2018
- ||| Trial completion, Trial primary completion date: Detection of Chlamydia (CT) and Gonorrhea (NG) (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=700, Completed, Sponsor: Meridian Bioscience, Inc.
Trial primary completion date: Nov 2017 --> Apr 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2014
- ||||||| VivaGel (astodrimer vaginal) / Starpharma
Trial completion: Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) (clinicaltrials.gov) - Dec 7, 2017
P3, N=637, Completed, Sponsor: Starpharma Pty Ltd
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2014 Active, not recruiting --> Completed
- | moxifloxacin intravenous / Generic mfg.
Trial termination: Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine (clinicaltrials.gov) - Dec 7, 2017
P1, N=15, Terminated, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- | Enrollment closed, Trial primary completion date: STI Screening as a Combined HIV Prevention Platform for MSM in Peru (clinicaltrials.gov) - Dec 4, 2017
P=N/A, N=150, Active, not recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Jun 2018
- | Trial completion: SeTPAT: Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection (clinicaltrials.gov) - Nov 30, 2017
P=N/A, N=150, Completed, Sponsor: Institute of Tropical Medicine, Belgium
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Jun 2018 Active, not recruiting --> Completed
- | GamLPV (intranasal Bordetella pertussis vaccine) / Gamaleya Research Institute
Enrollment closed, P1 data: A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine (clinicaltrials.gov) - Nov 29, 2017
P1, N=36, Active, not recruiting, Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | murepavadin (POL7080) / Spexis
Trial completion: Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia (clinicaltrials.gov) - Nov 28, 2017
P2, N=25, Completed, Sponsor: Polyphor Ltd.
Recruiting --> Active, not recruiting Terminated --> Completed
- | doxycycline / Generic mfg.
Trial completion, Trial primary completion date, IO biomarker: Doxycycline in Human Pulmonary Tuberculosis (clinicaltrials.gov) - Nov 27, 2017
P2, N=40, Completed, Sponsor: National University Hospital, Singapore
Terminated --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2017
- | Trial completion, Enrollment change, Trial primary completion date: Evaluation of Systemic Microvascular Endothelial Dysfunction in Patients Presenting With Infective Endocarditis (clinicaltrials.gov) - Nov 27, 2017
P=N/A, N=25, Completed, Sponsor: National Institute of Cardiology, Laranjeiras, Brazil
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Completed | N=50 --> 25 | Trial primary completion date: Jan 2018 --> Aug 2017
- | Enrollment change, Trial withdrawal: An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients (clinicaltrials.gov) - Nov 24, 2017
P=N/A, N=0, Withdrawn, Sponsor: Penn State University
Recruiting --> Completed | N=50 --> 25 | Trial primary completion date: Jan 2018 --> Aug 2017 N=42 --> 0 | Not yet recruiting --> Withdrawn
- Trial termination: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830 (clinicaltrials.gov) - Nov 22, 2017
P1, N=62, Terminated, Sponsor: GlaxoSmithKline
N=42 --> 0 | Not yet recruiting --> Withdrawn Withdrawn --> Terminated; Study data is currently under review.
- | Enrollment change, Trial withdrawal: Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults (clinicaltrials.gov) - Nov 20, 2017
P2a/2b, N=0, Withdrawn, Sponsor: PATH
Withdrawn --> Terminated; Study data is currently under review. N=72 --> 0 | Recruiting --> Withdrawn
- | flucloxacillin sodium / Generic mfg.
Trial primary completion date: FANATIC: Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=30, Recruiting, Sponsor: Radboud University
N=72 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Mar 2018
- Enrollment change, Trial withdrawal, Trial primary completion date: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830 (clinicaltrials.gov) - Nov 17, 2017
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2017 --> Mar 2018 N=78 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Nov 2017 --> Feb 2017
- | triamcinolone acetonide / Generic mfg.
Trial completion, Enrollment change: A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=32, Completed, Sponsor: University of North Carolina, Chapel Hill
N=78 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Nov 2017 --> Feb 2017 Recruiting --> Completed | N=50 --> 32
- |||||| Enrollment open, Trial primary completion date: Phase III Clinical Study of Efficacy and Safety of Vaccae (clinicaltrials.gov) - Nov 14, 2017
P3, N=10000, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Recruiting --> Completed | N=50 --> 32 Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2017 --> Nov 2017
- | Enrollment closed, Enrollment change: PCS: Preventing Congenital Syphilis (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=60386, Active, not recruiting, Sponsor: Tulane University School of Public Health and Tropical Medicine
Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2017 --> Nov 2017 Recruiting --> Active, not recruiting | N=6000 --> 60386
- | Myobloc (rimabotulinumtoxin B) / Supernus Pharma, Eisai
Enrollment closed, Trial primary completion date: Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=20, Active, not recruiting, Sponsor: University Hospital of North Norway
Recruiting --> Active, not recruiting | N=6000 --> 60386 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Mar 2018
- | Trial primary completion date: The Diagnostic Validity of the Urea Breath Test (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=1200, Recruiting, Sponsor: Seoul National University Bundang Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Mar 2018 Trial primary completion date: Jan 2017 --> Jan 2018
- | Trial completion, Trial primary completion date: RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care (clinicaltrials.gov) - Nov 1, 2017
P3, N=8665, Completed, Sponsor: MJM Bonten
Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Oct 2017
- | nacubactam (RG6080) / Roche, Meiji Seika
Trial completion: A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants (clinicaltrials.gov) - Oct 31, 2017
P1, N=21, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Oct 2017 Active, not recruiting --> Completed
- | prednisone / Generic mfg.
Trial completion: Pred-ART: Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone (clinicaltrials.gov) - Oct 27, 2017
P3, N=240, Completed, Sponsor: University of Cape Town
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial primary completion date, Adherence: TXT4MED: Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging (clinicaltrials.gov) - Oct 27, 2017
P=N/A, N=40, Recruiting, Sponsor: University of Arizona
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Aug 2018
- | nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: DATiC: Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) (clinicaltrials.gov) - Oct 27, 2017
P4, N=200, Completed, Sponsor: University of Cape Town
Trial primary completion date: Dec 2017 --> Aug 2018 Recruiting --> Completed
- | Trial completion, Enrollment change: Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=53, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Completed Active, not recruiting --> Completed | N=70 --> 53
- | Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Trial completion: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - Oct 19, 2017
P2b, N=71, Completed, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed | N=70 --> 53 Active, not recruiting --> Completed
- |||| Trial primary completion date: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen (clinicaltrials.gov) - Oct 17, 2017
P3, N=1080, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Nov 2017
- |||| Trial primary completion date: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children (clinicaltrials.gov) - Oct 17, 2017
P3, N=96, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Trial primary completion date: Jun 2017 --> Nov 2017 Trial primary completion date: Mar 2017 --> Nov 2017
- | Trial completion, Trial primary completion date: coliST131: Epidemiology of ST131 in Besançon University Hospital (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=300, Completed, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial primary completion date: Mar 2017 --> Nov 2017 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017
- ||| Trial completion: A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults (clinicaltrials.gov) - Oct 17, 2017
P1, N=144, Completed, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017 Active, not recruiting --> Completed
- | Trial suspension, Trial primary completion date, Endobronchial ultrasound: Role of EBUS-TBNA in Diagnosing TB in Mediastinal/Hilar Lymph Nodes (clinicaltrials.gov) - Oct 16, 2017
P=N/A, N=50, Suspended, Sponsor: Centre Hospitalier Universitaire Saint Pierre
Active, not recruiting --> Completed Recruiting --> Suspended | Trial primary completion date: Dec 2015 --> Dec 2017
- | Trial initiation date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Oct 16, 2017
P=N/A, N=328, Recruiting, Sponsor: University of British Columbia
Recruiting --> Suspended | Trial primary completion date: Dec 2015 --> Dec 2017 Initiation date: Jun 2013 --> Mar 2014
- Minocin for injection (minocycline intravenous) / Melinta Therap
Trial primary completion date: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults (clinicaltrials.gov) - Oct 16, 2017
P1, N=50, Recruiting, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Initiation date: Jun 2013 --> Mar 2014 Trial primary completion date: Sep 2017 --> Dec 2017
- | Trial completion, Trial primary completion date: Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis (clinicaltrials.gov) - Oct 13, 2017
P3, N=800, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
Trial primary completion date: Sep 2017 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2016
- | Trial completion, Enrollment change, HEOR: Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=40, Completed, Sponsor: University of Schleswig-Holstein
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2016 Enrolling by invitation --> Completed | N=100 --> 40
- |||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial completion, Trial primary completion date: Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam (clinicaltrials.gov) - Oct 11, 2017
P2, N=224, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Enrolling by invitation --> Completed | N=100 --> 40 Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016
- | Trial primary completion date: PK Study of Anti-TB Drugs (clinicaltrials.gov) - Oct 10, 2017
P1, N=60, Recruiting, Sponsor: University of Oxford
Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Dec 2016 Trial primary completion date: Dec 2016 --> Feb 2018